Prescribing patterns for elderly Parkinson's disease in Japan using claims data

Not Applicable

• Conditions: s disease; Parkinson&#39

• Registration Number: JPRN-UMIN000046823
• Lead Sponsor: Takeda Pharmaceutical Company Limited

Brief Summary

Of the 18 million people, 39,731 met eligibility criteria, with a PD prevalence of 1.21 per 100 people aged 75 yo and over. Levodopa was the most prescribed anti-PD drug (overall: 85.4%; aged 75 yo and over: 88.3%). Older patients were mainly switched from levodopa monotherapy to adjunctive prescriptions, with monoamine oxidase type B inhibitors, non-ergot dopamine agonists and zonisamide used as adjunctive therapies. Adjunct levodopa tended to be prescribed at levodopa doses of 300 mg, regardless of age.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-03
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 39731

Inclusion Criteria

Not provided

Exclusion Criteria

Patients under 30 years of age and patients with Parkinson's disease syndrome

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prescribing patterns of anti-Parkinson's diseases drugs